Key statistics
As of last trade Syndax Pharmaceuticals Inc (1T3:FRA) traded at 17.10, -6.04% below its 52-week high of 18.20, set on Feb 12, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 17.10 |
|---|---|
| High | 17.10 |
| Low | 17.10 |
| Bid | 17.20 |
| Offer | 17.50 |
| Previous close | 17.60 |
| Average volume | 68.57 |
|---|---|
| Shares outstanding | 86.91m |
| Free float | 85.32m |
| P/E (TTM) | -- |
| Market cap | 1.78bn USD |
| EPS (TTM) | -3.61 USD |
Data delayed at least 15 minutes, as of Feb 16 2026 07:03 GMT.
More ▼
Announcements
- Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference
- Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
- Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
- Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
- Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
More ▼
